GWLLOTCFood and Kindred ProductsFiscal year ends December 31

GOLDENWELL BIOTECH, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.65+0.05 (+8.33%)

Close on Oct 19, 2026

Market cap: $64.35M
P/E (TTM): –
Dividend yield: –

GOLDENWELL BIOTECH, INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	0.00	0.00	0.00	0.05	0.02	0	0
Cost of Revenue	0.00	0.00	0.00	0.02	0.01	0	0
Gross Profit	0.00	0.00	0.00	0.03	0.01	0	0
Selling, General & Admin	–	–	–	–	0.13	0.01	0.00
General & Administrative	0.11	0.12	0.12	1.01	0.13	–	–
Operating Expenses	0.11	0.12	0.12	1.01	-0.13	0.01	0.00
Operating Income	-0.11	-0.12	-0.12	-0.99	-0.12	–	–
Interest Expense	0.01	0.01	0.00	–	0	0	0
Other Non-Operating Income	–	–	–	0.00	0.00	0.00	0
Pretax Income	–	-0.13	-0.12	–	-0.12	-0.01	0.00
Income Tax Expense	0	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	–	-0.13	-0.12	-0.99	0.12	-0.01	–
Net Income	-0.30	-0.13	-0.12	-0.99	-0.12	-0.01	0.00
EPS (Basic)(per share)	–	–	–	–	0.00	0.00	0.00
EPS (Diluted)(per share)	0.00	0.00	0.00	–	0.00	0.00	0.00
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	91	80	76
Shares Outstanding (Diluted, Weighted)(shares)	99	99	99	–	91	80	76
Non-Interest Expense	–	0.01	0.00	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 21.8%
Operating margin: -208729.1%
Net margin: -512940.0%
Return on equity, FY2025: 151.7%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 11.1%

Valuation

P/E ratio: –
Price to sales: 1170000.00
Price to book: –
Dividend yield: –